Bone Biologics (NASDAQ:BBLG) Issues Earnings Results

Bone Biologics (NASDAQ:BBLG) issued its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02, FiscalAI reports.

Bone Biologics Stock Performance

Bone Biologics stock opened at $0.38 on Tuesday. The stock’s 50 day simple moving average is $0.52 and its two-hundred day simple moving average is $1.09. Bone Biologics has a fifty-two week low of $0.37 and a fifty-two week high of $2.39. The stock has a market cap of $1.04 million, a price-to-earnings ratio of -0.28 and a beta of 0.90.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Bone Biologics

Bone Biologics Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.

The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research.